CLASS II Drug recall · Reported 31 Oct 2018 · FDA Enforcement Report

Actoplus Met XR (Pioglitazone recalled by Teva Pharmaceuticals U

Teva Pharmaceuticals USA is recalling Actoplus Met XR (Pioglitazone and metformin HCl extended -release) tablets, 15 mg/1000 mg, distributed nationwide in the US. The recall was initiated on 6 Aug 2018 and the FDA has classified it as Class II.

Check your package

Lot, batch or date codesBulk Lot no 1250668, 15 mg/1000 mg Bulk product No # 1274150, no NDC Codes, bulk exp. date 05/2020 & 10/2020
Quantity recalledN/A

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

Recall details

Recall number
D-0102-2019
FDA event ID
80790
Recalling firm
Teva Pharmaceuticals USA, North Wales, PA
Classification
Class II
Status
Terminated
Recall initiated
6 Aug 2018
FDA classified
25 Oct 2018
Reported
31 Oct 2018
Type
Voluntary: Firm initiated
Customers notified by
Letter
Reason category
Packaging Defects

Timeline

6 Aug 2018Recall initiated by company
25 Oct 2018Classified by FDA+80 days
31 Oct 2018Published in enforcement report+6 days

Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.

Reason for recall

Defective Delivery System: There is a potential for some tablets to be missing the laser drilling which might affect drug release.

Packaging recalls include wrong labels, wrong products in the wrong bottle, missing leaflets, short-filled or empty capsules and seals that fail.

Product as listed by the FDA

PIO&METFORMIN 15/1000 mg Tab 1 (Pioglitazone and Metformin XT) tablets, Takeda Brand Name: Actoplus Met XR (Pioglitazone and metformin HCl extended -release) tablets, 15 mg/1000 mg, packaged in a fiber drum, Application Holder Takeda Pharmaceuticals, U.S.A. Inc. One Takeda Parkway, Deerfield, IL 60015

Where it was distributed

Product was distributed throughout the United States. Bulk product was distributed to Takeda, Deerfield, IL and may have been further distributed.

Nationwide Illinois

Questions about this recall

Why was it recalled?

Defective Delivery System: There is a potential for some tablets to be missing the laser drilling which might affect drug release.

Which lots are affected?

Bulk Lot no 1250668, 15 mg/1000 mg Bulk product No # 1274150, no NDC Codes, bulk exp. date 05/2020 & 10/2020

Where was it sold?

Product was distributed throughout the United States. Bulk product was distributed to Takeda, Deerfield, IL and may have been further distributed.

What should I do if I have it?

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

What does Class II mean?

Class II means the product may cause temporary or medically reversible health problems, or the probability of serious harm is remote.

Read the official FDA notice · Source record retrieved 26 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.

Other products in this recall event

6 other products · FDA event 80790

This product is part of a recall event; the main page for the event is Paliperidone Extended Release Tablets 9 mg recalled.

More recalls from Teva Pharmaceuticals USA

All 280

Other Actoplus Met (pioglitazone recalls

All 2
ReportedClassRecallCompanyReasonWhere
DrugCLASS IIActoplus met XR (pioglitazone and metformin HCl recalledTakeda Development Center AmericasOther9 states